

---

---

CREDIT NUMBER 6975-GY

# Financing Agreement

(COVID-19 Emergency Response Project – Additional Financing)

between

CO-OPERATIVE REPUBLIC OF GUYANA

and

INTERNATIONAL DEVELOPMENT ASSOCIATION

---

---

**FINANCING AGREEMENT**

AGREEMENT dated as of the Signature Date between CO-OPERATIVE REPUBLIC OF GUYANA ("Recipient") and INTERNATIONAL DEVELOPMENT ASSOCIATION ("Association"), for the purpose of providing additional financing for the Original Project and activities related to the Original Project (as defined in the Appendix to this Agreement).

WHEREAS, the Association, acting as administrator of the Health Emergency Preparedness and Response Multi-Donor Trust Fund, has also decided to provide additional financing for the Original Project and activities related to the Original Project, and for this purpose the Recipient and the Association intend to sign the HEPR Grant Agreement (as defined in the Appendix to this Agreement).

The Recipient and the Association hereby agree as follows:

**ARTICLE I — GENERAL CONDITIONS; DEFINITIONS**

- 1.01. The General Conditions (as defined in the Appendix to this Agreement) apply to and form part of this Agreement.
- 1.02. Unless the context requires otherwise, the capitalized terms used in this Agreement have the meanings ascribed to them in the General Conditions or in the Appendix to this Agreement.

**ARTICLE II — FINANCING**

- 2.01. The Association agrees to extend to the Recipient a credit, which is deemed as Concessional Financing for purposes of the General Conditions, in an amount equivalent to three million five hundred thousand Special Drawing Rights (SDR 3,500,000) (variously, "Credit" and "Financing"), to assist in financing Parts 1(a)(viii)-(ix), 1(b)(vii)-(x), and 2 of the project as such project is described in Schedule 1 to this Agreement ("Project").
- 2.02. The Recipient may withdraw the proceeds of the Financing in accordance with Section III of Schedule 2 to this Agreement.
- 2.03. The Maximum Commitment Charge Rate is one-half of one percent (1/2 of 1%) per annum on the Unwithdrawn Financing Balance.

- 2.04. The Service Charge is three-fourths of one percent (3/4 of 1%) per annum on the Withdrawn Credit Balance.
- 2.05. The Payment Dates are June 1 and December 1 in each year.
- 2.06. The principal amount of the Credit shall be repaid in accordance with the repayment schedule set forth in Schedule 3 to this Agreement.
- 2.07. The Payment Currency is Dollar.

**ARTICLE III — PROJECT**

- 3.01. The Recipient declares its commitment to the objectives of the Project and the MPA Program. To this end, the Recipient shall carry out the Project through the MOH in accordance with the provisions of Article V of the General Conditions and Schedule 2 to this Agreement.

**ARTICLE IV — EFFECTIVENESS; TERMINATION**

- 4.01. The Additional Conditions of Effectiveness consist of the following:
  - (a) The Project Operations Manual has been updated and adopted by the Recipient, through the MOH, in form and substance satisfactory to the Association.
  - (b) The Vaccine Delivery and Distribution Manual has been adopted by the Recipient, through the MOH, in form and substance satisfactory to the Association.
  - (c) The HEPR Grant Agreement has been executed and delivered and all conditions precedent to its effectiveness have been fulfilled.
- 4.02. The Effectiveness Deadline is the date ninety (90) days after the Signature Date.
- 4.03. For purposes of Section 10.05(b) of the General Conditions, the date on which the obligations of the Recipient under this Agreement (other than those providing for payment obligations) shall terminate is twenty (20) years after the Signature Date.

**ARTICLE V — REPRESENTATIVE; ADDRESSES**

- 5.01. The Recipient's Representative is its minister in charge of finance.
- 5.02. For purposes of Section 11.01 of the General Conditions: (a) the Recipient's address is:

Ministry of Finance  
49 Main and Urquhart Streets  
Georgetown  
Co-operative Republic of Guyana; and

(b) the Recipient's Electronic Address is:

Telex:	Facsimile:	E-mail:
592-227-3992	592-226-1284	minister@finance.gov.gy

- 5.03. For purposes of Section 11.01 of the General Conditions: (a) The Association's address is:

International Development Association  
1818 H Street, N.W.  
Washington, D.C. 20433  
United States of America; and

(b) the Association's Electronic Address is:

Telex:	Facsimile:
248423 (MCI)	1-202-477-6391

AGREED as of the Signature Date.

**CO-OPERATIVE REPUBLIC OF GUYANA**

**By**




\_\_\_\_\_  
**Authorized Representative**

**Name:** Ashni Singh  
**Title:** Senior Minister, Office of the President  
**Date:** 02-Jul-2021

**INTERNATIONAL DEVELOPMENT ASSOCIATION**

**By**



\_\_\_\_\_  
**Authorized Representative**

**Name:** Kathryn Ann Funk  
**Title:** Acting Country Director  
**Date:** 01-Jul-2021

## SCHEDULE 1

### Project Description

The objectives of the Project are to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Guyana.

The Project constitutes a phase of the MPA Program, and consists of the following parts:

#### 1. Emergency Response to COVID-19.

- (a) ***Case Detection, Confirmation, Contact Tracing, Recording, and Reporting*** Strengthening disease surveillance systems, public health laboratories and epidemiological capacity for early detection of COVID-19 cases through:
  - (i) improving the diagnostic capacity for COVID-19 in the National Public Health Reference Laboratory;
  - (ii) establishing COVID-19 diagnostic facilities in selected hospital labs;
  - (iii) improving general laboratory services to enhance clinical management of COVID-19 cases;
  - (iv) enhancing the provision of rapid results for COVID-19 screening;
  - (v) strengthening epidemiological and surveillance capacity;
  - (vi) establishing laboratory capacity in the Georgetown Public Hospital Corporation Annex;
  - (vii) recruiting, training and deploying contact tracers to cover all regions;
  - (viii) developing and implementing logistical data and tracking systems for Project COVID-19 Vaccine deployment and other immunization programs, including ancillary supplies and staff involved; and
  - (ix) training staff involved in the use of immunization surveillance and tracking systems.

- (b) **Health System Strengthening.** Strengthening the health system for more effective treatment of symptomatic COVID-19 patients, and isolation and quarantine of asymptomatic COVID-19 cases through:
- (i) expanding capacity for intensive care units;
  - (ii) establishing specialized medical care units in selected hospitals;
  - (iii) increasing bed capacity in hospitals, isolation and quarantine facilities;
  - (iv) increasing availability and improving existing cold-chain, storage facilities, and delivery systems for Project COVID-19 Vaccines;
  - (v) strengthening psycho-social support to vulnerable households;
  - (vi) promoting preventive actions to limit spread of communicable diseases and increasing community awareness and participation;
  - (vii) supporting Guyana's health sector in the purchase and deployment of Project COVID-19 Vaccines;
  - (viii) recruiting and training staff for Project COVID-19 Vaccine deployment and for the expanded program of immunization;
  - (ix) developing and implementing citizen and community engagement mechanisms to build trust in immunizations; and
  - (x) implementing a centralized hydroclave disposal system for waste generated by immunization activities.

**2. Implementation Management and Monitoring and Evaluation.**

Supporting Project implementation activities, including administrative, coordination management, procurement, financial management, environmental, social, reporting functions; and carrying out capacity building on pandemic response and preparedness.

**3. Supporting National and Sub-National Prevention and Preparedness, and Health System Resilience.**

Strengthening analytical and assessment capacity of the MOH and other relevant ministries of the Recipient on health system strengthening, preparedness and resilience, and on multisectoral actions for better health outcomes, through:

- (a) promoting a One Health approach, including:
  - (i) carrying out a joint external evaluation and training and dissemination activities;
  - (ii) carrying out a performance of veterinary services assessment; and
  - (iii) carrying out a One Health bridging workshop and a training program on resilience, multisectoral training in health and agriculture, data collection, cross-sectoral surveillance and integrated monitoring and reporting systems; and
- (b) strengthening the delivery and quality of care through an assessment of the performance of the health system and its ability to deliver essential services, including carrying out a health facility and a patient experience survey.



## SCHEDULE 2

### Project Execution

#### Section I. Implementation Arrangements

##### A. Institutional Arrangements

1. The Recipient, through the MOH, shall carry out the Project in accordance with this Agreement, the Project Operations Manual and the Vaccine Delivery and Distribution Manual.
2. The Recipient, through the MOH, shall maintain at all times during Project implementation, professional staff in adequate numbers and with terms of reference, qualifications and functions acceptable to the Association and set forth in the Project Operations Manual.

##### B. Project Operations Manual

1. The Recipient, through the MOH, shall update, adopt and thereafter carry out, the Project in accordance with an operations manual acceptable to the Association ("Project Operations Manual"), which shall contain detailed work flow, methods and procedures for the implementation of the Project, including but not limited to: (a) administration and coordination arrangements, including placement of necessary human resources for Project implementation; (b) performance indicators of the Project; (c) monitoring and evaluation; (d) financial management guidelines and procedures; (e) corruption and fraud measures; (f) roles and responsibilities of various agencies and stakeholders in the implementation of the Project; and (g) Personal Data collection and processing requirements in accordance with good international practice.
2. Except as the Association shall otherwise agree in writing, the Recipient, through the MOH, shall not amend or waive, or permit to be amended or waived any provision of the Project Operations Manual.
3. In case of conflict between the provisions of the Project Operations Manual and this Agreement, those of this Agreement shall prevail.

##### C. Environmental and Social Standards

1. The Recipient, through the MOH, shall ensure that the Project is carried out in accordance with the Environmental and Social Standards, in a manner acceptable to the Association.

2. Without limitation upon paragraph 1 above, the Recipient, through the MOH, shall ensure that the Project is implemented in accordance with the Environmental and Social Commitment Plan ("ESCP"), in a manner acceptable to the Association. To this end, the Recipient, through the MOH, shall ensure that:
  - (a) the measures and actions specified in the ESCP are implemented with due diligence and efficiency, as provided in the ESCP;
  - (b) sufficient funds are available to cover the costs of implementing the ESCP;
  - (c) policies and procedures are maintained, and qualified and experienced staff in adequate numbers are retained to implement the ESCP, as provided in the ESCP; and
  - (d) the ESCP, or any provision thereof, is not amended, repealed, suspended or waived, except as the Association shall otherwise agree in writing, as specified in the ESCP, and ensure that the revised ESCP is disclosed promptly thereafter.
3. In case of any inconsistencies between the ESCP and the provisions of this Agreement, the provisions of this Agreement shall prevail.
4. The Recipient, through the MOH, shall ensure that:
  - (a) all measures necessary are taken to collect, compile, and furnish to the Association through regular reports, with the frequency specified in the ESCP, and promptly in a separate report or reports, if so requested by the Association, information on the status of compliance with the ESCP and the environmental and social instruments referred to therein, all such reports in form and substance acceptable to the Association, setting out, *inter alia*: (i) the status of implementation of the ESCP; (ii) conditions, if any, which interfere or threaten to interfere with the implementation of the ESCP; and (iii) corrective and preventive measures taken or required to be taken to address such conditions; and
  - (b) the Association is promptly notified of any incident or accident related to or having an impact on the Project which has, or is likely to have, a significant adverse effect on the environment, the affected communities, the public or workers in accordance with the ESCP, the environmental and social instruments referenced therein and the Environmental and Social Standards.
5. The Recipient, through the MOH, shall establish, publicize, maintain and operate an accessible grievance mechanism, to receive and facilitate resolution of concerns and grievances of Project-affected people, and take all measures necessary and

appropriate to resolve, or facilitate the resolution of, such concerns and grievances, in a manner acceptable to the Association.

6. The Recipient, through the MOH, shall ensure that all bidding documents and contracts for civil works under the Project include the obligation of contractors, subcontractors and supervising entities to: (a) comply with the relevant aspects of ESCP and the environmental and social instruments referred to therein; and (b) adopt and enforce codes of conduct that should be provided to and signed by all workers, detailing measures to address environmental, social, health and safety risks, and the risks of sexual exploitation and abuse, sexual harassment and violence against children, all as applicable to such civil works commissioned or carried out pursuant to said contracts.
7. The Recipient, through the MOH, shall take the following measures related to the use of military or security forces in the implementation of Project activities, in a manner satisfactory to the Association:
  - (a) adopt and enforce standards, protocols and codes of conduct for the selection and use of military or security forces, and screen such personnel to verify that they have not engaged in past unlawful or abusive behavior, including sexual exploitation and abuse (“SEA”), sexual harassment (“SH”) or excessive use of force;
  - (b) ensure that the military or security forces is deployed in accordance with the relevant requirements of ESSs and the ESCP;
  - (c) ensure that the military or security forces are adequately instructed and trained, prior to deployment and on a regular basis, on the use of force and appropriate conduct (including in relation to civilian-military engagement, SEA and SH, and other relevant areas), as set out in the Environmental and Social Management Framework; and
  - (d) ensure that the stakeholder engagement activities under the Stakeholder Engagement Plan include a communication strategy on the involvement of military or security forces under the Project; and
  - (e) ensure that any concerns or grievances regarding the conduct of the military or security forces are received, monitored, documented (taking into account the need to protect confidentiality), resolved through the Project’s grievance mechanism; and reported to the Association no later than one (1) day after being received.

**D. Vaccine Delivery and Distribution Manual**

1. Without limitation on Section B above, in order to ensure adequate implementation of Part 1(b)(vii) of the Project, the Recipient, through the MOH, shall prepare and adopt a manual for Project COVID-19 Vaccine delivery and distribution ("Vaccine Delivery and Distribution Manual"), in form and substance satisfactory to the Association, which shall include:
  - (a) rules and procedures for prioritizing intra-country Project COVID-19 Vaccine allocation following principles established in the WHO Fair Allocation Framework, including an action plan setting out the timeline and steps for implementing such rules;
  - (b) rules and procedures establishing minimum standards for Project COVID-19 Vaccine management and monitoring, including medical and technical criteria, communications and outreach plan, cold chain infrastructure, and other related logistics infrastructure;
  - (c) rules and procedures for processing and collection of Personal Data in accordance with good international practice; and
  - (d) vaccine distribution plan, including action plan setting out timeline and steps for immunization.
2. The Recipient, through the MOH, shall carry out the Project in accordance with this Agreement, the Project Operations Manual, and the Vaccine Delivery and Distribution Manual.
3. Except as the Association shall otherwise agree, the Recipient, through the MOH, shall not assign, amend, abrogate, or waive the provisions of the Project Operations Manual or the Vaccine Delivery and Distribution Manual without prior approval of the Association.
4. In the event of any conflict between the provisions of the Vaccine Delivery and Distribution Manual and this Agreement, the provisions of this Agreement shall prevail.

**E. Use of Military and Security Forces**

1. All activities carried out by military or security forces under the Project shall be under the control of the MOH and shall be undertaken exclusively for the purposes related to the Project.
2. All goods, works, services, incremental operating costs, and training financed by the Credit proceeds may be used by military or security forces under the direction

and control of the MOH and strictly in accordance with the Project Operations Manual and other arrangements or protocols that the Association may require for carrying out these activities.

3. Except as the Association may otherwise agree, the Recipient, through the MOH, shall ensure that that the ownership of any assets generated, goods procured, and works constructed by military or security forces out of the Credit proceeds shall be transferred to, or shall vest, with the MOH or any equivalent or appropriate line ministry or agency agreed with the Association.

**F. Standards for COVID-19 Vaccine Approval**

All Project COVID-19 Vaccines shall satisfy the Vaccine Approval Criteria.

**Section II. Project Monitoring, Reporting and Evaluation**

1. The Recipient shall furnish to the Association each Project Report not later than forty-five (45) days after the end of each calendar semester, covering the calendar semester.
2. Except as may otherwise be explicitly required or permitted under this Agreement or as may be explicitly requested by the Association, in sharing any information, report or document related to the activities described in Schedule 1 of this Agreement, the Recipient shall ensure that such information, report or document does not include Personal Data.

**Section III. Withdrawal of the Proceeds of the Financing**

**A. General**

Without limitation upon the provisions of Article II of the General Conditions and in accordance with the Disbursement and Financial Information Letter, the Recipient may withdraw the proceeds of the Financing to finance Eligible Expenditures; in the amount allocated and, if applicable, up to the percentage set forth against each Category of the following table:

Category	Amount of the Credit Allocated (expressed in SDR)	Percentage of Expenditures to be Financed (inclusive of Taxes)
(1) Goods, works, non-consulting services, consulting services, Operating Costs, and Training and Workshops for Parts 1(a)(viii), 1(a)(ix), 1(b)(vii), 1(b)(viii), 1(b)(ix), 1(b)(x) of the Project	3,220,000	100%
(2) Goods, works, non-consulting services, consulting services, Operating Costs, and Training and Workshops for Part 2 of the Project	280,000	100%
<b>TOTAL AMOUNT</b>	3,500,000	

**B. Withdrawal Conditions: Withdrawal Period**

1. Notwithstanding the provisions of Part A above, no withdrawal shall be made for payments made prior to the Signature Date, except that withdrawals up to an aggregate amount not to exceed (SDR 2,800,000) may be made for payments made prior to this date but on or after August 15, 2020, for Eligible Expenditures: for the purposes of Part 1(b)(vii). Eligible Expenditures for such retroactive financing shall be limited to the Project COVID-19 Vaccines of Sinopharm and Johnson & Johnson, or such other Project COVID-19 Vaccine that meets all the eligibility criteria provided under IDA financing, including: (a) meeting the Vaccine Approval Criteria; (b) complying with the Procurement Regulations; and (c) receiving the Association's review and no-objection on the eligibility of the related Project COVID-19 Vaccine purchasing contract.
2. The Closing Date is June 30, 2023.

**C. Military and Security Actors**

The Recipient further undertakes that no Financing proceeds or resources may be used for law-enforcement, security, or military purposes or for any payments made to any law-enforcement, security, or military forces without the Association's express approval.

**SCHEDULE 3**

**Repayment Schedule**

<b>Date Payment Due</b>	<b>Principal Amount of the Credit repayable (expressed as a percentage)*</b>
On each June 1 and December 1:	
commencing December 1, 2031, to and including June 1, 2041	1%
commencing December 1, 2041, to and including June 1, 2061	2%

\* The percentages represent the percentage of the principal amount of the Credit to be repaid, except as the Association may otherwise specify pursuant to Section 3.05 (b) of the General Conditions.

## APPENDIX

### Definitions

1. "Anti-Corruption Guidelines" means, for purposes of paragraph 5 of the Appendix to the General Conditions, the "Guidelines on Preventing and Combating Fraud and Corruption in Projects Financed by IBRD Loans and IDA Credits and Grants", dated October 15, 2006 and revised in January 2011 and as of July 1, 2016.
2. "Category" means a category set forth in the table in Section III.A of Schedule 2 to this Agreement.
3. "COVAX Facility" means the COVID-19 Vaccine Global Access Facility, a mechanism through which demand and resources are pooled to support the availability of, and equitable access to, COVID-19 vaccines for all economies, and which is coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO.
4. "COVID-19" means the coronavirus disease caused by the 2019 novel coronavirus (SARS-CoV-2).
5. "Environmental and Social Commitment Plan" or "ESCP" means the environmental and social commitment plan for the Project, dated June 21, 2021, as the same may be amended from time to time in accordance with the provisions thereof, which sets out the material measures and actions that the Recipient shall carry out or cause to be carried out to address the potential environmental and social risks and impacts of the Project, including the timeframes of the actions and measures, institutional, staffing, training, monitoring and reporting arrangements, and any environmental and social instruments to be prepared thereunder.
6. "Environmental and Social Standards" or "ESSs" means, collectively:
  - (i) "Environmental and Social Standard 1: Assessment and Management of Environmental and Social Risks and Impacts";
  - (ii) "Environmental and Social Standard 2: Labor and Working Conditions";
  - (iii) "Environmental and Social Standard 3: Resource Efficiency and Pollution Prevention and Management";
  - (iv) "Environmental and Social Standard 4: Community Health and Safety";
  - (v) "Environmental and Social Standard 5: Land Acquisition, Restrictions on Land Use and Involuntary Resettlement";
  - (vi) "Environmental and Social Standard 6: Biodiversity Conservation and Sustainable Management of Living Natural Resources";
  - (vii) "Environmental and Social Standard 7: Indigenous Peoples/Sub-Saharan Historically Underserved Traditional Local Communities";
  - (viii) "Environmental and Social Standard 8: Cultural Heritage";
  - (ix) "Environmental and Social Standard 9: Financial Intermediaries"; and
  - (x) "Environmental and Social Standard 10: Stakeholder Engagement and



- Information Disclosure”; effective on October 1, 2018, as published by the Association.
7. “General Conditions” means the “International Development Association General Conditions for IDA Financing, Investment Project Financing”, dated December 14, 2018 (revised on August 1, 2020 and April 1, 2021).
  8. “Georgetown Public Hospital Corporation Annex” means the annex to the Georgetown Public Hospital Corporation at Liliendaal.
  9. “HEPR Grant Agreement” means the grant agreement for the COVID-19 Emergency Response Project between the Recipient and the International Development Association, as such grant agreement may be amended from time to time (Grant No. TF0B6163-GY). “HEPR Grant Agreement” includes all appendices, schedules and agreements supplemental to the HEPR Grant Agreement.
  10. “MOH” means the Recipient’s Ministry of Health, or any successor acceptable to the Association.
  11. “MPA Program” means the global emergency multiphase programmatic approach program designed to assist countries to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness.
  12. “National Public Health Reference Laboratory” means the Recipient’s referral laboratory responsible for public health responses, providing support to public and private laboratories, and granting certification for operation to laboratories.
  13. “One Health” means a coordinated, collaborative, multidisciplinary and cross-sectoral approach that recognizes the interconnection between the health of humans, animals and ecosystems, and that addresses potential or existing risks originating from animal-human-ecosystem interfaces.
  14. “Operating Costs” means the reasonable costs, as shall have been approved by the Association, for the incremental expenses incurred on account of Project implementation, consisting of vehicle operation and maintenance, communication and insurance costs, banking charges, rental expenses, office (and office equipment) maintenance, utilities, document duplication/printing, consumables, travel cost and per diem for Project staff for travel linked to the implementation of the Project.
  15. “Original Financing Agreement” means the financing agreement for the COVID 19 Emergency Response Project between the Co-operative Republic of Guyana and the International Development Association, dated December 15, 2020

(Credit No. 6802-GY). "Original Financing Agreement" includes all appendices, schedules and agreements supplemental to the Original Financing Agreement.

16. "Original Project" means the Project described in the Original Financing Agreement.
17. "Personal Data" means any information relating to an identified or identifiable individual. An identifiable individual is one who can be identified by reasonable means, directly or indirectly, by reference to an attribute or combination of attributes within the data, or combination of the data with other available information. Attributes that can be used to identify an identifiable individual include, but are not limited to, name, identification number, location data, online identifier, metadata and factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of an individual.
18. "Procurement Regulations" means, for purposes of paragraph 87 of the Appendix to the General Conditions, the "World Bank Procurement Regulations for IPF Borrowers", dated November 2020.
19. "Project COVID-19 Vaccine" means a vaccine for the prevention of COVID-19, authorized by the Recipient's national regulatory authority for distribution, marketing and administration within the territory of the Recipient, and acquired or deployed under the Project; "Project COVID-19 Vaccines" means the plural thereof.
20. "Project Operations Manual" means the manual referred to under Section I.B.1 of Schedule 2 to this Agreement.
21. "Signature Date" means the later of the two dates on which the Recipient and the Association signed this Agreement and such definition applies to all references to "the date of the Financing Agreement" in the General Conditions.
22. "Stringent Regulatory Authority" means a National Regulatory Authority ("NRA") that is classified by WHO as a Stringent Regulatory Authority.
23. "Training and Workshops" means the reasonable costs, as shall have been approved by the Association, for training and workshops conducted under the Project, including tuition, travel and subsistence costs for training and workshop participants, costs associated with securing the services of trainers and workshop speakers, rental of training and workshop facilities, preparation and reproduction of training and workshop materials, and other costs directly related to training course and workshop preparation and implementation (but excluding goods and consulting services).
24. "Vaccine Approval Criteria" means that the Project COVID-19 Vaccine: (a) has received regular or emergency licensure or authorization from at least one of the

Stringent Regulatory Authorities identified by WHO for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; (b) has received the WHO Prequalification or WHO Emergency Use Listing; or (c) has met such other criteria as may be agreed in writing between the Recipient and the Association.

25. "Vaccine Delivery and Distribution Manual" means the Recipient's manual referred to in Section I.D of Schedule 2 to this Agreement, as the same may be amended from time to time with the Association's prior written approval.
26. "WHO" means the World Health Organization.
27. "WHO Emergency Use Listing" means a risk-based procedure for assessing and listing by WHO of unlicensed vaccines, therapeutics, and in vitro diagnostics with the aim of expediting the availability of these products to people affected by a declared public health emergency.
28. "WHO Fair Allocation Framework" means the rules which govern the allocation of vaccines to participants in the COVAX Facility, as developed by WHO, subject to periodic review by the COVAX Facility.
29. "WHO Prequalification" means a service provided by WHO to assess the quality, safety, and efficacy of medical products for priority diseases, and which are intended for United Nations and international procurement to developing countries.

